These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 19044214)

  • 1. Changes in brain function during administration of venlafaxine or placebo to normal subjects.
    Leuchter AF; Cook IA; DeBrota DJ; Hunter AM; Potter WZ; McGrouther CC; Morgan ML; Abrams M; Siegman B
    Clin EEG Neurosci; 2008 Oct; 39(4):175-81. PubMed ID: 19044214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment.
    Hunter AM; Leuchter AF; Cook IA; Abrams M
    Acta Psychiatr Scand; 2010 Dec; 122(6):461-9. PubMed ID: 20384600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in brain function of depressed subjects during treatment with placebo.
    Leuchter AF; Cook IA; Witte EA; Morgan M; Abrams M
    Am J Psychiatry; 2002 Jan; 159(1):122-9. PubMed ID: 11772700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QEEG Theta Cordance in the Prediction of Treatment Outcome to Prefrontal Repetitive Transcranial Magnetic Stimulation or Venlafaxine ER in Patients With Major Depressive Disorder.
    Bares M; Brunovsky M; Novak T; Kopecek M; Stopkova P; Sos P; Höschl C
    Clin EEG Neurosci; 2015 Apr; 46(2):73-80. PubMed ID: 24711613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurophysiologic effects of repeated exposure to antidepressant medication: are brain functional changes during antidepressant administration influenced by learning processes?
    Hunter AM; Cook IA; Abrams M; Leuchter AF
    Med Hypotheses; 2013 Dec; 81(6):1004-11. PubMed ID: 24112999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early changes in prefrontal activity characterize clinical responders to antidepressants.
    Cook IA; Leuchter AF; Morgan M; Witte E; Stubbeman WF; Abrams M; Rosenberg S; Uijtdehaage SH
    Neuropsychopharmacology; 2002 Jul; 27(1):120-31. PubMed ID: 12062912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
    Hunter AM; Leuchter AF; Morgan ML; Cook IA
    Am J Psychiatry; 2006 Aug; 163(8):1426-32. PubMed ID: 16877657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo.
    Hunter AM; Leuchter AF; Morgan ML; Cook IA; Abrams M; Siegman B; DeBrota DJ; Potter WZ
    Neuropsychopharmacology; 2005 Apr; 30(4):792-9. PubMed ID: 15637637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midline and right frontal brain function as a physiologic biomarker of remission in major depression.
    Cook IA; Hunter AM; Abrams M; Siegman B; Leuchter AF
    Psychiatry Res; 2009 Nov; 174(2):152-7. PubMed ID: 19853417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder.
    Hunter AM; Muthén BO; Cook IA; Leuchter AF
    J Psychiatr Res; 2010 Jan; 44(2):90-8. PubMed ID: 19631948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder.
    Bares M; Brunovsky M; Kopecek M; Novak T; Stopkova P; Kozeny J; Sos P; Krajca V; Höschl C
    Eur Psychiatry; 2008 Aug; 23(5):350-5. PubMed ID: 18450430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does prior antidepressant treatment of major depression impact brain function during current treatment?
    Hunter AM; Cook IA; Leuchter AF
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):711-20. PubMed ID: 22445212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial.
    van Kerkhoven LA; Laheij RJ; Aparicio N; De Boer WA; Van den Hazel S; Tan AC; Witteman BJ; Jansen JB
    Clin Gastroenterol Hepatol; 2008 Jul; 6(7):746-52; quiz 718. PubMed ID: 18424191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project.
    Leuchter AF; McGough JJ; Korb AS; Hunter AM; Glaser PE; Deldar A; Durell TM; Cook IA
    J Psychiatr Res; 2014 Jul; 54():11-8. PubMed ID: 24726639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study.
    Bares M; Brunovsky M; Kopecek M; Stopkova P; Novak T; Kozeny J; Höschl C
    J Psychiatr Res; 2007; 41(3-4):319-25. PubMed ID: 16889798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression.
    Luthringer R; Toussaint M; Schaltenbrand N; Bailey P; Danjou PH; Hackett D; Guichoux JY; Macher JP
    Psychopharmacol Bull; 1996; 32(4):637-46. PubMed ID: 8993085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression.
    Hunter AM; Ravikumar S; Cook IA; Leuchter AF
    Acta Psychiatr Scand; 2009 Apr; 119(4):266-73. PubMed ID: 19077131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
    Kornstein SG; Kocsis JH; Ahmed S; Thase M; Friedman ES; Dunlop BW; Yan B; Pedersen R; Ninan PT; Li T; Keller M
    Int Clin Psychopharmacol; 2008 Nov; 23(6):357-63. PubMed ID: 18854724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of venlafaxine on cognitive functions and quantitative EEG in healthy volunteers.
    Siepmann T; Mueck-Weymann M; Oertel R; Kirch W; Pittrow D; Siepmann M
    Pharmacopsychiatry; 2008 Jul; 41(4):146-50. PubMed ID: 18651343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.